Eli Lilly takes aim at illicit market for its experimental weight-loss drug
Eli Lilly sues six firms to shut down a black‑market trade in its experimental obesity drug retatrutide.
3 independently sourced, verified trend briefs about this subject.
Newsylist includes a story here only after at least four independent sources support it and its brief passes the verification check. The qualifying coverage spans 1 news category, from Jun 23, 2026 through Aug 12, 2026.
The cards below are ordered newest first. Each opens the underlying timeline, source list, coverage velocity and verification context; raw or extractive-only records are excluded.
Eli Lilly sues six firms to shut down a black‑market trade in its experimental obesity drug retatrutide.
Eli Lilly is planning a Q1 2027 FDA application for retatrutide following new data on weight loss and A1C improvements.
Speculation is mounting over whether Donald Trump was the mystery 79-year-old patient who received an experimental weight loss drug.